Chloroquine
- Generic Name
- Chloroquine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3
- CAS Number
- 54-05-7
- Unique Ingredient Identifier
- 886U3H6UFF
- Background
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Chloroquine was granted FDA Approval on 31 October 1949.
- Indication
Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.
- Associated Conditions
- Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
- Conditions
- COVID-19
- Interventions
- Other: Best standard of careDrug: non-RAS blocking antihypertensivesDrug: Thromboprophylaxis
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 500
- Registration Number
- NCT04351724
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Tirol, Austria
🇦🇹Wilhelminenspital, Vienna, Austria
🇦🇹SMZ Ost Donauspital, Vienna, Austria
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
- Conditions
- Sars-CoV2Covid-19Symptomatic Condition
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
- Target Recruit Count
- 137
- Registration Number
- NCT04351191
- Locations
- 🇵🇰
Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan
🇵🇰Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan
🇵🇰Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan
Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
- Conditions
- Coronavirus InfectionCOVID
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 5
- Registration Number
- NCT04349371
- Locations
- 🇺🇸
Columbia University Irving Medical Center/NYP, New York, New York, United States
Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds
- Conditions
- Coronavirus InfectionAsymptomatic ConditionSARS-CoV-2COVID-19
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
- Target Recruit Count
- 125
- Registration Number
- NCT04346667
- Locations
- 🇵🇰
Mayo Hospital, Lahore, Punjab, Pakistan
🇵🇰Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan
🇵🇰Expo Covid Center, Lahore, Punjab, Pakistan
Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection
- Conditions
- COVID-19SARS-CoV InfectionSevere Acute Respiratory Syndrome (SARS) PneumoniaClinical Trial
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Target Recruit Count
- 152
- Registration Number
- NCT04342650
- Locations
- 🇧🇷
Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
- Conditions
- Coronavirus Infection
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT04341727
- Locations
- 🇺🇸
Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Chloroquine for Mild Symptomatic and Asymptomatic COVID-19
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 5
- Registration Number
- NCT04333628
- Locations
- 🇮🇱
Haemek Medical Center, Afula, Israel
Chloroquine as Antiviral Treatment in Coronavirus Infection 2020
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Wroclaw Medical University
- Target Recruit Count
- 16
- Registration Number
- NCT04331600
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland
🇵🇱Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland
The Vietnam Chloroquine Treatment on COVID-19
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2021-05-24
- Target Recruit Count
- 10
- Registration Number
- NCT04328493
- Locations
- 🇻🇳
Cho Ray Hospital, Ho Chi Minh City, Vietnam
🇻🇳Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam
🇻🇳Can Gio COVID Hospital, Ho Chi Minh City, Vietnam
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2
- Conditions
- SARS-CoV InfectionSevere Acute Respiratory Syndrome (SARS) Pneumonia
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Target Recruit Count
- 278
- Registration Number
- NCT04323527
- Locations
- 🇧🇷
Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.